Diarrhea - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the drug development landscape of the drug development for diarrhea including molecules at pre-clinical, pre-registration, and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentation such as indications coverage, therapies employed, route of administration, therapeutic modality, targets, and mechanism of action.

Overview of the drug development pipeline for diarrhea

Diarrhea causes dehydration due to the fluid loss. It also causes frequent, loose, and watery bowel movements. This condition usually lasts for a few days and can be acute or chronic. Osmotic diarrhea, secretory diarrhea, exudative diarrhea, and traveler’s diarrhea are the types of diarrhea. Diarrhea generally occurs due to a host of bacterial, viral, and parasitic organisms, most of which are spread by feces-contaminated water. Patients suffering from this condition experience blood in the stool, nausea, abdominal cramps, abdominal pain, and fever. Technavio’s market research analysts have predicted that with the introduction of rehydration with oral rehydration salt, zinc supplements, rehydration with intravenous fluids, and antidiarrheal medications as some of the most promising approaches to treat diarrhea, the global diarrhea market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the discovery and phase II developmental stage. For instance, sponsors such as Albireo Pharma developed A3384 and Drais Pharmaceuticals developed ASP7147, which are under phase II development stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under phase I/II and pre-registration developmental stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under pre-clinical, discovery, phase I, and phase III stages.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of diarrhea. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Ardelyx
• AzurRx
• GP Pharm

Therapeutic assessment of the drug development pipeline for diarrhea by route of administration

• Oral
• Subcutaneous
• Intramuscular
• Intranasal
• Rectum

The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration. As a result, majority of the molecules are administered orally.

Therapeutic assessment of the drug development pipeline for diarrhea by therapeutic modality

• Small molecule
• Vaccine
• Enzyme
• Peptide
• Biological
• Monoclonal antibody
• Oligomer

According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for diarrhea are being developed as small molecules. Small molecules bind with specific biological macromolecules and act as an effector inside the body.

Technavio’s pipeline analysis report provides detailed insights into the clinical trials landscape of diarrhea including molecules at the pre-clinical and discovery stages. The report provides detailed information on the Tier1, Tier2, and Tier 3 companies that are actively involved in the development of molecules for the treatment of diarrhea and the various development stages of these molecules. Additionally, the report also provides information on the molecules discontinued by companies.

The report offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations including route of administration (RoA) and target. With information on the development strategies adopted by companies and the number of molecules they are working on; the report also provides an estimate of the completion time for the development of these molecules. Furthermore, the report also provides information on the recruitment strategies companies adopt for clinical trials.

Key questions answered in the report include

• What are the molecules in the various development stages for diarrhea?
• What are the companies that are currently involved in the development of molecules for diarrhea?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.